JP2014534229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534229A5 JP2014534229A5 JP2014540200A JP2014540200A JP2014534229A5 JP 2014534229 A5 JP2014534229 A5 JP 2014534229A5 JP 2014540200 A JP2014540200 A JP 2014540200A JP 2014540200 A JP2014540200 A JP 2014540200A JP 2014534229 A5 JP2014534229 A5 JP 2014534229A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- agent
- leukemia
- tbl1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026339 F-box-like/WD repeat-containing protein TBL1X Human genes 0.000 claims description 8
- 101000835691 Homo sapiens F-box-like/WD repeat-containing protein TBL1X Proteins 0.000 claims description 8
- 101000835690 Homo sapiens F-box-like/WD repeat-containing protein TBL1Y Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 108010087042 Transducin Proteins 0.000 claims description 6
- 102000006612 Transducin Human genes 0.000 claims description 6
- 230000003081 coactivator Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 4
- 230000002071 myeloproliferative effect Effects 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 102000015735 Beta-catenin Human genes 0.000 claims description 2
- 108060000903 Beta-catenin Proteins 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 102100026353 F-box-like/WD repeat-containing protein TBL1XR1 Human genes 0.000 claims description 2
- 102100026338 F-box-like/WD repeat-containing protein TBL1Y Human genes 0.000 claims description 2
- 102000003964 Histone deacetylase Human genes 0.000 claims description 2
- 108090000353 Histone deacetylase Proteins 0.000 claims description 2
- 101000835675 Homo sapiens F-box-like/WD repeat-containing protein TBL1XR1 Proteins 0.000 claims description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000032839 leukemia Diseases 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556245P | 2011-11-06 | 2011-11-06 | |
| US61/556,245 | 2011-11-06 | ||
| PCT/US2012/063746 WO2013067547A1 (en) | 2011-11-06 | 2012-11-06 | METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534229A JP2014534229A (ja) | 2014-12-18 |
| JP2014534229A5 true JP2014534229A5 (OSRAM) | 2015-02-05 |
| JP6063472B2 JP6063472B2 (ja) | 2017-01-18 |
Family
ID=48192926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540200A Active JP6063472B2 (ja) | 2011-11-06 | 2012-11-06 | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9238030B2 (OSRAM) |
| EP (1) | EP2773607B1 (OSRAM) |
| JP (1) | JP6063472B2 (OSRAM) |
| KR (1) | KR102336767B1 (OSRAM) |
| CN (1) | CN103917514B (OSRAM) |
| AU (1) | AU2012332111B2 (OSRAM) |
| BR (1) | BR112014010584A2 (OSRAM) |
| CA (1) | CA2853491C (OSRAM) |
| EA (1) | EA027770B1 (OSRAM) |
| ES (1) | ES2624427T3 (OSRAM) |
| IL (1) | IL232452A (OSRAM) |
| MX (1) | MX354653B (OSRAM) |
| SG (1) | SG11201402056XA (OSRAM) |
| WO (1) | WO2013067547A1 (OSRAM) |
| ZA (1) | ZA201403003B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9725473B2 (en) * | 2015-07-28 | 2017-08-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
| US9963475B2 (en) * | 2015-07-28 | 2018-05-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
| WO2019229001A1 (en) * | 2018-05-30 | 2019-12-05 | Otto-Von-Guericke-Universität Magdeburg | Compounds for the treatment of jak2-v617f-associated cmn |
| CN119215047A (zh) * | 2024-10-11 | 2024-12-31 | 浙江大学 | 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2871493C (en) * | 2007-05-10 | 2017-03-28 | Dogwood Pharmaceuticals, Inc. | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
| US8304408B2 (en) * | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| EA030302B1 (ru) * | 2008-11-21 | 2018-07-31 | Форест Лэборетериз Холдингз Лимитед | Антрахинондиоксимы и их применение |
| BR112012002942A2 (pt) * | 2009-08-10 | 2015-10-13 | Epitherix Llc | indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes. |
| EP2470534A4 (en) | 2009-08-24 | 2013-02-27 | Merck Sharp & Dohme | JAK INHIBITION FOR BLOCKING TOXICITY ASSOCIATED WITH RNA INTERFERENCE |
| CN102665756A (zh) * | 2009-10-01 | 2012-09-12 | Csl有限公司 | 费城染色体阳性白血病的治疗方法 |
-
2012
- 2012-11-06 AU AU2012332111A patent/AU2012332111B2/en active Active
- 2012-11-06 CA CA2853491A patent/CA2853491C/en active Active
- 2012-11-06 MX MX2014005498A patent/MX354653B/es active IP Right Grant
- 2012-11-06 KR KR1020147015141A patent/KR102336767B1/ko active Active
- 2012-11-06 WO PCT/US2012/063746 patent/WO2013067547A1/en not_active Ceased
- 2012-11-06 US US13/670,377 patent/US9238030B2/en active Active
- 2012-11-06 SG SG11201402056XA patent/SG11201402056XA/en unknown
- 2012-11-06 ES ES12845590.4T patent/ES2624427T3/es active Active
- 2012-11-06 JP JP2014540200A patent/JP6063472B2/ja active Active
- 2012-11-06 CN CN201280054386.3A patent/CN103917514B/zh active Active
- 2012-11-06 EA EA201490937A patent/EA027770B1/ru not_active IP Right Cessation
- 2012-11-06 EP EP12845590.4A patent/EP2773607B1/en active Active
- 2012-11-06 BR BR112014010584A patent/BR112014010584A2/pt not_active IP Right Cessation
-
2014
- 2014-04-24 ZA ZA2014/03003A patent/ZA201403003B/en unknown
- 2014-05-04 IL IL232452A patent/IL232452A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523397A5 (OSRAM) | ||
| JP2014534229A5 (OSRAM) | ||
| Nath et al. | To evaluate the efficacy of intrathecal magnesium sulphate for hysterectomy under subarachnoid block with bupivacaine and fentanyl: A prospective randomized double blind clinical trial | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016518387A5 (OSRAM) | ||
| JP2016517434A5 (OSRAM) | ||
| JP2015528471A5 (OSRAM) | ||
| JP2013512898A5 (OSRAM) | ||
| JP2014502641A5 (OSRAM) | ||
| JP2019517587A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| EA200970435A1 (ru) | Лечение общих расстройств развития | |
| JP2014525454A5 (OSRAM) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| JP2013541583A5 (OSRAM) | ||
| JP2014533272A5 (OSRAM) | ||
| JP2015502926A5 (OSRAM) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2014139255A5 (OSRAM) | ||
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| JP2006502132A5 (OSRAM) | ||
| AR078170A1 (es) | Metodos para el tratamiento de tumores cerebrales | |
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib | |
| JP2020516663A5 (OSRAM) | ||
| JP2019524888A5 (OSRAM) |